Breaking Down Aier Eye Hospital Group Co., Ltd. Financial Health: Key Insights for Investors

Aier Eye Hospital Group's latest figures paint a nuanced picture for investors: Q3 2025 revenue of ¥5.98 billion (+3.83% YoY) and year-to-date revenue of ¥17.48 billion (+7.25% YoY) contribute to a TTM revenue of ¥22.17 billion even as market capitalization slid to ¥105.60 billion on December 19, 2025 (down 19.38% YoY); profitability shows strain with Q3 net profit attributable to shareholders at ¥1.06 billion (-24.12% YoY) and TTM net income of ¥3.22 billion (net margin 16.99%, ROE 17.87%, EPS ¥0.35, P/E 32.70), while balance-sheet metrics display expansion-total assets ¥35.84 billion (+7.76% year-end) and shareholders' equity ¥22.43 billion (+8.3%) with a moderate debt-to-equity of 29.53%-liquidity is solid (operating cash flow Q3 ¥5.08 billion, +18.14% YoY), valuation ratios show a premium (TTM P/E 30.75, forward P/E 25.10, P/S 5.26, P/B 5.21; market cap was ¥114.61 billion on July 1, 2025), risk vectors include Wang Vision Institute credit volatility (default probability peaked at 2.35% in 2023 and stabilized to 1.26% by mid-2025) and a ¥2.145 billion goodwill increase in 2024, and upside is evident in a targeted ¥29.81 billion revenue goal for 2027 (implying a 14% CAGR from 2025 levels) supported by rising domestic demand, network expansion, and technology investments-read on to unpack what these numbers mean for investment decisions.

Aier Eye Hospital Group Co., Ltd. (300015.SZ) - Revenue Analysis

• Q3 2025 revenue: ¥5.98 billion - +3.83% year-over-year (YoY).
• Year-to-date (YTD) revenue through Q3 2025: ¥17.48 billion - +7.25% YoY.
• H1 2025 revenue: ¥6.03 billion - +30% quarter-over-quarter (QoQ) and +3.02% YoY.
• Trailing twelve months (TTM) revenue: ¥22.17 billion, with quarterly revenue growth of 16%.
• Market capitalization (as of 2025-12-19): ¥105.60 billion - down 19.38% year-over-year.

• Service mix: growing contribution from premium refractive and cataract surgery segments increases average revenue per patient.
• Patient volume: rising domestic demand for eye-care services amid aging population trends and increasing myopia management in younger cohorts.
• Network expansion: new domestic hospitals and international partnerships add incremental capacity and cross-border patient referrals.
• Pricing & mix: selective premiumization and ancillary services (optical retail, diagnostics) lift realized revenue per visit.

• Capacity utilization: QoQ jumps (H1 2025 +30% QoQ) indicate recovery of elective procedures after seasonal/operational lulls.
• Geographic diversification: international expansion supports growth but introduces integration and margin variability.
• Competition & reimbursement: pricing sensitivity in certain mass-market segments could moderate unit revenue gains.

Aier Eye Hospital Group Co., Ltd. (300015.SZ) - Profitability Metrics

• Q3 2025 net profit attributable to shareholders: ¥1.06 billion (down 24.12% YoY)
• Year-to-date net profit (YTD): ¥3.11 billion (down 9.76% YoY)
• TTM net income: ¥3.22 billion
• TTM net profit margin: 16.99%
• TTM return on equity (ROE): 17.87%
• TTM earnings per share (EPS): ¥0.35; implied P/E ratio: 32.70

Aier Eye Hospital Group Co., Ltd. (300015.SZ) - Debt vs. Equity Structure

• Total assets increased to ¥35.84 billion (↑7.76% YoY vs. prior year-end).
• Shareholders' equity stood at ¥22.43 billion (↑8.3% YoY vs. prior year-end).
• Reported debt-to-equity ratio: 29.53%, reflecting a balanced capital mix.
• Financial leverage described as moderate - indicative of prudent capital management and room to support growth or withstand shocks.

• Interpretation: the rise in both assets and equity signals reinvestment and expansion (capex, network growth, M&A or working capital increases), while the modest D/E keeps interest and refinancing risk controlled.
• Liquidity and solvency context: with equity covering a large share of the asset base and a moderate D/E, Aier retains capacity to raise debt if needed for expansion without materially increasing risk.
• Investor takeaway: the capital structure supports growth-oriented strategies while maintaining financial stability; monitor net debt trends, interest coverage, and any off-balance liabilities in subsequent reports.

Aier Eye Hospital Group Co., Ltd. (300015.SZ) - Liquidity and Solvency

• Operating cash flow (Q3 2025): ¥5.08 billion (+18.14% YoY)
• Current ratio: 1.9x - sufficient short‑term liquidity to cover near‑term liabilities
• Quick ratio: 1.4x - liquid assets adequately cover immediate obligations
• Debt‑to‑equity ratio: 0.48 - moderate leverage, supportive of solvency
• Interest coverage ratio: 6.2x - comfortable ability to service interest expenses
• Solvency ratio: 38.5% - indicates solid buffer for long‑term obligations

• The increase in operating cash flow suggests improved operational efficiency and stronger collection/expense controls.
• Robust operating cash flow enhances capacity to pursue growth-hospital expansions, technology upgrades, and M&A-while maintaining liquidity headroom.
• Favorable liquidity and solvency metrics reduce refinancing risk and improve financial flexibility for strategic initiatives.

Aier Eye Hospital Group Co., Ltd. (300015.SZ) - Valuation Analysis

• TTM P/E: 30.75 - indicates investors are paying ~31× last twelve months' earnings.
• Forward P/E: 25.10 - implies expected earnings growth is already partially priced in.
• P/S: ¥5.26 and P/B: ¥5.21 - both signal a premium relative to many healthcare services peers.
• EV/Revenue: 5.33 and EV/EBITDA: 21.21 - suggest significant enterprise-level valuation multiple requiring strong margin outlook to justify.
• Market cap (as of 2025-07-01): ¥114.61 billion - demonstrates sizable institutional and retail confidence.

Aier Eye Hospital Group Co., Ltd. (300015.SZ) - Risk Factors

• Credit risk at U.S. subsidiary - Wang Vision Institute: default probability peaked at 2.35% in 2023 and moderated to 1.26% by mid-2025, indicating a meaningful spike in credit stress followed by partial stabilization.
• Rising U.S. operational and regulatory costs: increased compliance, staffing, and credentialing costs have materially compressed clinic-level margins in the U.S. market.
• Global input-cost pressure: inflation and supply-chain disruptions have raised consumable and equipment costs, squeezing gross margins across markets.
• Goodwill and impairment risk: goodwill rose by ¥2.145 billion in 2024, increasing the company's exposure to potential impairment charges if cash flows underperform expectations.
• Leverage: debt-to-equity ratio at 29.53% denotes moderate financial leverage but limits flexibility if earnings decline.
• International exposure: operations across multiple jurisdictions create currency translation risk and sensitivity to geopolitical events that could disrupt patient flows or cross-border capital.

• Key monitoring metrics for investors:
  • Receivables aging and collection trends from Wang Vision Institute.
  • Quarterly SG&A and labor-cost trends in U.S. clinics versus revenue.
  • Goodwill impairment testing outcomes and sensitivity assumptions.
  • Net debt, interest coverage, and trend in debt-to-equity versus covenants.
  • FX translation impacts and country-level revenue mix.

Aier Eye Hospital Group Co., Ltd. (300015.SZ) - Growth Opportunities

• Demographic and epidemiological drivers: China's population aging and high myopia prevalence support secular demand for ophthalmic care-China's 65+ cohort is roughly 13-14% of the population (2023), while myopia prevalence among school-aged children and young adults routinely exceeds 50% in many surveys.
• Geographic expansion: Targeted rollout into county-level, rural and lower-tier city markets increases addressable patient pools and reduces competition intensity versus first-tier urban centers.
• Technology & service differentiation: Investments in advanced procedures and diagnostics-ZEISS SMILE refractive surgery, OCTA (optical coherence tomography angiography), premium intraocular lenses and femtosecond/bladeless cataract platforms-improve clinical outcomes and enable higher ASPs (average selling prices) per procedure.
• International market optionality: Exposure to or partnerships in the U.S. healthcare market offers upside, given projections of a ~10.5% CAGR for the U.S. healthcare market through 2032.
• Essential-service resilience: High-volume, essential procedures such as cataract surgery and diabetic retinopathy management provide revenue stability and defensive cash flow through regulatory or macroeconomic cycles.

• Patient-volume scaling: Expanding networks and referral flows from primary care and optometry increase surgical caseload potential-greater utilization of high-margin procedures (e.g., premium IOLs, refractive surgery) can lift revenue per visit.
• Margin expansion levers: Greater penetration of premium services, improved OR utilization rates, supply-chain negotiation on consumables and platform-centralized administrative functions offer sustainable margin upside.
• Capital allocation & targets: Achieving the ¥29.81 billion revenue objective by 2027 requires ~14% CAGR from 2025 levels; execution hinges on new hospital openings, same-store patient growth, and successful monetization of advanced procedures.
• Regulatory and payer dynamics: Focus on essential, high-demand procedures (cataract, urgent retinal care) reduces sensitivity to pricing regulation while private-pay and premium-service adoption can offset reimbursement pressure.